Barclays analyst Andrew Mok lowered the firm’s price target on DaVita (DVA) to $149 from $160 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. The firm continues to think Medicare is the most stable, Medicaid the most uncertain, and the Affordable Care Act exchanges are inflecting positively from both a fundamental and policy perspective.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVA:
- Private Markets: Databricks valued at over $100B in latest fundraising
- DaVita price target lowered to $140 from $145 at BofA
- DaVita Announces Strategic Initiative for Operational Efficiency
- DaVita increases existing share repurchase authorization by $2B
- Berkshire trimmed Apple, DaVita, Charter, Bank of America stakes in Q2